107 related articles for article (PubMed ID: 12448851)
1. [Gene sequencing analysis of DNA gyrase and topoisomerase IV as levofloxacin resistance in Streptococcus pneumoniae].
Miyamoto H; Murase M
Kansenshogaku Zasshi; 2002 Oct; 76(10):898-9. PubMed ID: 12448851
[No Abstract] [Full Text] [Related]
2. Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.
Zheng X; Johnson C; Lu Y; Yanagihara R; Hollingshead S; Crain M; Benjamin W; Waites KB
Int J Antimicrob Agents; 2001 Oct; 18(4):373-8. PubMed ID: 11691571
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.
Lim S; Bast D; McGeer A; de Azavedo J; Low DE
Emerg Infect Dis; 2003 Jul; 9(7):833-7. PubMed ID: 12890324
[TBL] [Abstract][Full Text] [Related]
4. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Browne FA; Clark C; Bozdogan B; Dewasse BE; Jacobs MR; Appelbaum PC
Int J Antimicrob Agents; 2002 Aug; 20(2):93-9. PubMed ID: 12297357
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000.
Critchley IA; Blosser-Middleton RS; Jones ME; Karlowsky JA; Karginova EA; Thornsberry C; Sahm DF
Int J Antimicrob Agents; 2002 Aug; 20(2):100-7. PubMed ID: 12297358
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
7. Clonal spread of levofloxacin-resistant streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009.
Rodríguez-Avial I; Ramos B; Ríos E; Cercenado E; Ordobás M; Sanz JC;
Antimicrob Agents Chemother; 2011 May; 55(5):2469-71. PubMed ID: 21383091
[TBL] [Abstract][Full Text] [Related]
8. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
[TBL] [Abstract][Full Text] [Related]
9. Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.
de Cueto M; Rodríguez JM; Soriano MJ; López-Cerero L; Venero J; Pascual A
J Clin Microbiol; 2008 Apr; 46(4):1558-60. PubMed ID: 18287316
[TBL] [Abstract][Full Text] [Related]
10. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.
Smith HJ; Nichol KA; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2002 Jun; 49(6):893-5. PubMed ID: 12039880
[No Abstract] [Full Text] [Related]
11. Fluoroquinolone resistance in Streptococcus pyogenes.
Richter SS; Diekema DJ; Heilmann KP; Almer LS; Shortridge VD; Zeitler R; Flamm RK; Doern GV
Clin Infect Dis; 2003 Feb; 36(3):380-3. PubMed ID: 12539083
[TBL] [Abstract][Full Text] [Related]
12. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.
Kays MB; Smith DW; Wack ME; Denys GA
Pharmacotherapy; 2002 Mar; 22(3):395-9. PubMed ID: 11898897
[TBL] [Abstract][Full Text] [Related]
14. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
15. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
17. Detection of parC mutations in Streptococcus pneumoniae by Real-time PCR and Taqman-MGB probes.
Alonso R; Mateo E; Cisterna R
J Microbiol Methods; 2007 Apr; 69(1):214-7. PubMed ID: 17275939
[TBL] [Abstract][Full Text] [Related]
18. Incidence and epidemiology of levofloxacin resistance in Streptococcus pneumoniae: experience from a tertiary referral hospital in England.
Orr D; Wilkinson P; Moyce L; Martin S; George R; Pichon B
J Antimicrob Chemother; 2010 Mar; 65(3):449-52. PubMed ID: 20019170
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
Urban C; Rahman N; Zhao X; Mariano N; Segal-Maurer S; Drlica K; Rahal JJ
J Infect Dis; 2001 Sep; 184(6):794-8. PubMed ID: 11517444
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.
Onodera Y; Okuda J; Tanaka M; Sato K
Antimicrob Agents Chemother; 2002 Jun; 46(6):1800-4. PubMed ID: 12019093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
